A new paper outlines strategies to strengthen primary care pipeline in medical education, including mitigating administrative burdens, leveraging AI, and enriching student experiences. The authors emphasize the need for well-thought-out approaches to nudge the trend in a positive direction, rather than a single fix.
A new study reveals that p53 mutations in cancer cells can limit the effectiveness of immunotherapy by manipulating cellular metabolism, specifically through autophagy. Removing these mutant forms of p53 restores mTORC1 activity and reduces autophagy, making tumors more vulnerable to immune attack.
Scientists at Hackensack Meridian Health's CDI Lab published two companion papers explaining the 'exhaustion' of key immune cells. The first paper identified Id proteins as determinants of exhausted CD8+ T cell fate, while the second paper revealed CTCF's role in dynamic enhancer activation and invariant barriers.
Scientists have discovered that fat tissue can be hijacked by tumor cells, leading to its spread throughout the body. The fat tissue releases adipomes, which deliver a 'lipid code' that reprograms cancer cells, boosting their growth and invasiveness.
A nationwide study reveals a rapidly-evolving epidemic of community-associated multidrug resistant Klebsiella pneumoniae across the US, with over 2,000 samples screened from 42 states. The bacteria's genetic blueprint provides critical updates for public health and potential treatment options.
The symposium brought together a diverse pool of medical researchers to share groundbreaking studies on emerging technologies in medicine. The event highlighted pioneering approaches that are transforming patient outcomes, showcasing how Hackensack Meridian Health is paving the way for novel therapies.
The Applied Immunological Research Symposium (AIRS) brought together renowned scientists to share groundbreaking findings on T cell exhaustion and its connection to vaccine interception. Keynote speaker Rafi Ahmed presented data showing how blocking PD-1 reawakens a core population of 'stem-like' T cells, unleashing them to fight disease.
The study reveals that the interplay between EZH2 and Ca2+ signaling pathways can be harnessed to improve CAR T-cell efficacy in tumor control while preventing graft-versus-host disease. This balance allows for effective cancer treatment while minimizing transplant rejection.
A team of scientists at the Hackensack Meridian Center for Discovery and Innovation (CDI) has made a significant breakthrough in treating deadly non-tuberculous mycobacteria (NTM) infections. They have developed new compounds, including rifamycin candidates, which show promise in treating M. abscessus and other rapidly growing NTMs.
A team from Hackensack Meridian Health found that during the deepest sleep, breathing patterns become independent of brain activity, unlike lighter sleep or wakefulness. This study provides new insights into how internal brain states interact with peripheral rhythms like respiration.
A team of CDI scientists has identified the genetic basis of Acinetobacter baumannii's resistance to Cefiderocol, a last-line antibiotic. The study provides insights into the evolution of resistance and highlights the need for integrated surveillance strategies to prevent further resistance.
A revised approach to measuring treatment success for patients with chronic graft-versus-host disease has been proposed by the National Institutes of Health Consensus Project Task Force. The new criteria aim to capture clinically meaningful improvements in skin involvement, leading to better patient outcomes and more effective treatments.
Candida auris is a highly virulent fungus spreading globally, affecting 6.5 million people annually with high mortality rates. New review highlights strategies for combating its spread, including vaccination and treatment, as well as improving diagnostics and surveillance mechanisms.
Researchers at CDI Lab have identified two protein transcription factors, Tcf1 and Lef1, as critical modulators of T cell fate in the thymus. This discovery could lead to novel approaches in treating immune deficiencies, autoimmune diseases, and optimizing immunotherapies in cancer treatment.
Researchers have developed a novel platform to study human tuberculosis, allowing for accurate modeling of the disease's transmission. The Transmission Simulation System (TSS) mimics the airborne transmission of TB with unparalleled realism, enabling the study of vulnerabilities and strategies to interrupt transmission.
A new study suggests tailoring TB treatment to disease severity could improve patient outcomes and prevent the spread of drug-resistant strains. By identifying patients with less severe forms of TB, treatment courses can be safely shortened, reducing the risk of treatment failure and relapse.
A new study published in the Proceedings of the National Academy of Science demonstrates a critical enzyme pathway in maintaining immune cell activity. The research suggests that histone deacetylase (Hdac1) plays a crucial role in preventing excessive decline of effectiveness in exhausted cells.
Scientists have engineered a new drug candidate to target the deadly Mycobacterium abscessus infection, which is growing threat among immunocompromised patients and those with certain lung diseases. The new findings offer a promising solution for cystic fibrosis patients who are most endangered by M. abscessus infections.
Scientists have successfully collected and profiled lung biomarkers from human breath, developing animal models to identify key markers for early detection of metastatic lung tumors. The research establishes a scientific roadmap for an exhaled-breath test, which may revolutionize the diagnosis and surveillance of human lung diseases.
Scientists from Hackensack Meridian Health have identified a new potential pathway for developing vaccines against tuberculosis by targeting marginal zone B (MZB) cells, a natural response to TB infection. The discovery suggests that boosting MZB cell activity could provide reliable and durable protection against the disease.
Chronic Chagas Disease can cause irreversible heart damage due to the destruction of adipose tissue by Trypanosoma cruzi, releasing particles that induce dysfunction. The study reveals that adipome release regulates immunometabolic signaling and promotes inflammation in cardiac remodeling.
A clinical study published in Microbiology Spectrum found that COVID-19 vaccines still provide a robust immune response in immunocompromised individuals, including cancer patients undergoing treatment. This finding is crucial for clinicians and patients, as it suggests vaccination can help prevent infection and disease progression.
A meta-analysis of New Jersey clinical trials from 2017 to 2022 reveals an uptick in diversity among trial participants, with 97% reporting on race and/or ethnicity. Despite this progress, there is still work to be done to match U.S. Census demographics, but the study suggests recent efforts are having a positive impact.
Researchers at the John Theurer Cancer Center have co-authored a study on oral decitabine-cedazuridine therapy, which is now shown to be pharmacologically and pharmacodynamically equivalent to its intravenous counterpart. This innovation has significant potential for patient benefit and improved comfort in cancer treatment.
The Xue lab has made significant discoveries about the protein Tle3 and its role in regulating central memory T cells. By releasing Tle3's regulation, researchers were able to accelerate the formation of central memory T cells, leading to a more robust immune response.
A new study by the CDI Lab at NIH has assessed the rise of hypervirulent strains of Klebsiella pneumoniae, a deadly bacteria that can cause pneumonia and UTIs. The study found that a vaccine approach could be effective in combating these new strains.
A recent study by researchers from Hackensack Meridian Health found that recurrent fevers in children increased significantly during the first year of the COVID-19 pandemic. The study suggests that these fevers may be more common than previously thought and could have been overlooked in non-pandemic times.
The CDI published a study tracking nasal swabs of thousands of patients in New Jersey, providing new insights into the pandemic's peak. The results highlight the importance of vaccination, reinforcing the positive impact of COVID-19 vaccination and public health benefits of genotypic surveillance.
Researchers have identified a key protein in the body's innate ability to fight systemic fungal infections. The study found that C5a and its downstream effects are crucial for immune cells to clear the fungus Candida albicans when it overtakes natural defenses.
A new study published in the International Journal of Molecular Sciences suggests that COVID-19 targets female fat tissue for replication, sparring the lungs and preventing pulmonary damage. This theory may explain why men are more susceptible to severe infections and higher death rates during the pandemic.
The COVID Support Our Schools (SOS) program, developed by Hackensack Meridian School of Medicine, assisted 11 school districts and one Boys and Girls Club in historically underserved areas across New Jersey. The program provided personalized task forces with medical students and faculty experts to address various challenges such as vac...
A critical new pathway to treating glioblastoma, a deadly brain tumor, may be found in the complex diversity of tumor tissue. CDI scientists identified lipids with potential therapeutic value, highlighting the importance of targeting signaling pathways in relation to cell function and resistance to therapy.
A Hackensack Meridian health doctor and bioethicist argues that surgeons' subjective assessments can lead to 'ableist' biases in patient treatment. The author proposes using algorithms to aid doctors in making more data-driven decisions, reducing assumptions about patients' quality of life.
A new oral drug candidate, JSF-2659, has been developed to eradicate the bacteria causing gonorrhea. It works by simultaneously targeting two molecular targets, making it effective against resistant strains and reducing the risk of drug resistance.
The Hackensack Meridian Center for Discovery and Innovation's CDI laboratory has identified critical regulators controlling T-cell homeostasis. The findings could lead to improved cancer therapies and vaccines of the future by modulating the human immune system.
New anti-tuberculosis treatment strategies and drug development have made progress, but big challenges remain, including latent TB and the COVID-19 pandemic impact. The authors see promise in prioritizing drug combinations and accelerating approval of shorter treatment regimens.
Scientists at Hackensack Meridian Center for Discovery and Innovation have discovered a novel mechanism of immune 'memory' that could improve vaccine effectiveness. The Tcf1 transcription factor plays a crucial role in recognizing threats the immune system has faced before, and researchers believe it may be possible to enhance this imm...
The CDI laboratory has identified a complex natural pathway that melanoma hijacks to metastasize. The pathway centers around the silencing of bone morphogenetic protein 6 (BMP6), leading to abnormal cell signaling and increased cancer cell motility.
Scientists from Hackensack Meridian Center for Discovery and Innovation have uncovered the mechanism of action of a novel anti-tuberculosis drug, triaza-coumarin, which is effective in inhibiting TB disease from within by boosting its on-target activity by two orders of magnitude.
The Hackensack Meridian Center for Discovery and Innovation has developed the EV-CATCHER methodology, identifying and capturing tiny pieces of genetic material. This technology shows promise in diagnosing and treating diseases such as cancer early on.
A new study published in JCI Insights found that COVID-19 convalescent plasma treatment with high levels of antibodies is safe and significantly improves clinical outcomes. The treatment was effective in non-mechanically ventilated patients, with a survival rate of 88.9% at the 30-day mark.
A new therapy stimulating immune system response against cancer shows an acceptable safety profile when used alone or with checkpoint inhibitors. BMS-986178 demonstrates manageable adverse events and no dose-limiting toxicities, suggesting its potential as a treatment for patients with solid tumors.
Researchers from Hackensack Meridian Center for Discovery and Innovation and University of Michigan have created a portable 'lab on a chip' that can identify COVID-19 antibodies in human blood in just 15 minutes, significantly faster than current methods.
A novel combination of immunotherapy targeting CTLA-4 and PD-1 led to a rapid and complete response in a 19-year-old patient with stage 4 epithelioid sarcoma. The patient achieved complete remission within two weeks, resuming normal activities and physical examination.
Researchers found that changing gene expression first can improve the effectiveness of immunotherapies in battling aggressive pancreatic cancer. The study suggests a promising approach by administering an epigenetically-acting drug before immune checkpoint inhibition, doubling average survival time in preclinical models.
Researchers at Hackensack Meridian Health identified a drug that improves survival in critically ill COVID-19 patients. The study found a statistically significant decrease in hospital-related deaths among those who received tocilizumab, a monoclonal antibody used to treat rheumatoid arthritis and cancer treatments.
Scientists from Hackensack Meridian Health have discovered specific locations in the DNA where expression changes are imbalanced, indicating risks of cancer and other diseases. This finding provides a key to understanding the beginnings of both cancers and non-cancerous diseases.
Researchers at Hackensack Meridian Health's CDI laboratory have made a breakthrough in treating blood cancers, specifically leukemia. They identified a novel protein called Stem Cell Growth Factor Alpha (SCGFa), which has shown promise in preserving vascular function and promoting hematopoietic recovery following chemotherapy.